Get Ready for JPM: New Year Updates
Research - Revance Therapeutics (RVNC) just doesn’t stop. After hours on Thursday the company issued a 2017 update. Though we note nothing critical here, the company now … Continue Reading
PremiumSearch Results for cempra
Healthcare Lags: What To Look For Next
Insights - U.S. equities continue to sit at all-time highs, with financials, transportation, and energy leading the way, while biotech lags. The under-performance isn’t just from biotech/drug … Continue Reading
Read now
It Takes an Iron Stomach to Invest in Biotech Stocks
Insights - That was apparent yet again this week, with a slew of binary events that moved stocks in unexpected ways. Beginning with Zafgen (ZFGN). The developer … Continue Reading
Read now
Almost Two Months From the Top, Where Are We Now?
Research - We're nearly two months into the equity markets' deepest correction since August 2011. The S&P 500 bounced handily from its August lows at the end of September, and this week is close to retesting its latest level of resistance.
Premium
Yet Again, This Weekend May Be More Important Than This Week
Insights - Yet another choppy week for investors, and we’re going into another weekend in which decisions overseas will impact U.S. markets first thing on Monday. Greece submitted … Continue Reading
Read now
Biotech Finally Breaks Through the Wall
Research - Biotech is finally breaking out to new all-time highs, and you’ll be hard-pressed to find much red on your watch-list. We wrote about the current … Continue Reading
Read now
A Review of Our Latest Biotech Investing Ideas
Research - Even with Alexion Pharmaceuticals (ALXN) announcing Wednesday morning the acquisition of Synageva (GEVA) for a heady $8 billion, aggressive dip-buyers are still absent in the … Continue Reading
Premium